Skip to search formSkip to main contentSkip to account menu

kynostatin 272

Known as: 4-Thiazolidinecarboxamide, N-(1,1-dimethylethyl)-3- [2-hydroxy-3-[[2-[[(5-isoquinolinyloxy)acetyl]amino]-3- (methylthio)-1-oxopropyl]amino]-1-oxo-4-phenylbutyl]-,[4R-[3[2S*, 3S*(R*)],4R*]], KNI-272, kynostatin-272 
A synthetic peptide-based antiviral agent. As a peptidomimetic substrate containing an unnatural amino acid, allophenylnorstatine, KNI-272… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Anti-HIV AgentsHIV Protease InhibitorsOligopeptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Protease inhibitors
  • 2005
  • Corpus ID: 34900645
1999
1999
Microsomes Protease Inhibitor , KNI-272 , in Rat Liver Human Immunodeficiency Virus Type 1 Metabolic Characterization of a Tripeptide
1996
1996
Solution NMR Studies of the HIV-1 Protease/Inhibitor Complex : The HIV-1 Protease Catalytic Aspartyl Side-Chain Carboxyl Groups Have Distinct Protonation States in the Complex Formed with the…
1996
1996
KNI-272 : ANTIVIRAL FOR AIDS, HIV-1 PROTEASE INHIBITOR
1996
1996
Kynostatin 272.
1995
1995
Protease inhibitors.
Protease inhibitors (PRIs) are a diverse group of drugs which block an HIV-1 enzyme needed for the production of new viruses… 
1995
1995
Ongoing protease inhibitor trials.
There are several ongoing protease inhibitor trials for individuals with HIV. Hoffmann-LaRoche's trial of saquinavir is a phase… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)